Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine

JA Taverna, CN Hung, M Williams, R Williams, M Chen… - Lung Cancer, 2024‏ - Elsevier
Lung cancer is the leading cause of global cancer-related mortality resulting in∼ 1.8 million
deaths annually. Systemic, molecular targeted, and immune therapies have provided …

RUNX transcription factors: biological functions and implications in cancer

X Chen, L Wang, M Yang, W Zhao, J Tu, B Liu… - Clinical and …, 2024‏ - Springer
Runt-related transcription factors (RUNX) are a family of transcription factors that are
essential for normal and malignant hematopoietic processes. Their most widely recognized …

Characterization of nucleolar SUMO isopeptidases unveils a general p53-independent checkpoint of impaired ribosome biogenesis

J Dönig, H Mende, J Davila Gallesio, K Wagner… - Nature …, 2023‏ - nature.com
Ribosome biogenesis is a multi-step process, in which a network of trans-acting factors
ensures the coordinated assembly of pre-ribosomal particles in order to generate functional …

RUNX1-induced upregulation of PTGS2 enhances cell growth, migration and invasion in colorectal cancer cells

W Zheng, Y Guo, A Kahar, J Bai, Q Zhu, X Huang… - Scientific Reports, 2024‏ - nature.com
Colorectal cancer (CRC) arises via the progressive accumulation of dysregulation in key
genes including oncogenes and tumor-suppressor genes. Prostaglandin-endoperoxide …

Noxa inhibits oncogenesis through ZNF519 in gastric cancer and is suppressed by hsa-miR-200b-3p

J Shi, F Ding, D Dai, X Song, X Wu, D Yan, X Han… - Scientific Reports, 2024‏ - nature.com
Abstract While Phorbol-12-myristate-13-acetate-induced protein 1 (Noxa/PMAIP1) assumes
a pivotal role in numerous tumors, its clinical implications and underlying mechanisms of …

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy

M Ge, J Luo, Y Wu, G Shen, X Kuang - MedComm–Oncology, 2024‏ - Wiley Online Library
Synthetic lethality (SL), a genetic concept, has revolutionized the development of antitumor
therapies by providing avenues to target previously “undruggable” targets with enhanced …

Combination of RUNX1 inhibitor and gemcitabine mitigates chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated …

C She, C Wu, W Guo, Y **e, S Li, W Liu, C Xu… - Journal of Experimental …, 2023‏ - Springer
Background Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic
ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its …

The application of pancreatic cancer organoids for novel drug discovery

MK Melzer, Y Resheq, F Navaee… - Expert Opinion on Drug …, 2023‏ - Taylor & Francis
Introduction Pancreatic ductal adenocarcinoma presents with a dismal prognosis.
Personalized therapy is urgently warranted to overcome the treatment limitations of the 'one …

Deubiquitinating enzyme USP28 inhibitor AZ1 alone and in combination with cisplatin for the treatment of non-small cell lung cancer

Y Song, L Wang, Y Zheng, L Jia, C Li, K Chao, L Li… - Apoptosis, 2024‏ - Springer
Lung cancer is one of the most common malignant tumors. Despite decades of research, the
treatment of lung cancer remains challenging. Non-small cell lung cancer (NSCLC) is the …

[HTML][HTML] DNMT3A loss drives a HIF-1-dependent synthetic lethality to HDAC6 inhibition in non-small cell lung cancer

J Zhang, Y Zhao, R Liang, X Zhou, Z Wang… - … Pharmaceutica Sinica B, 2024‏ - Elsevier
Abstract DNMT3A encodes a DNA methyltransferase involved in development, cell
differentiation, and gene transcription, which is mutated and aberrant-expressed in cancers …